SPRAVATO® Treatment For Depression in Longview and East Texas

When Standard Treatments Haven't Been Enough

SPRAVATO® (esketamine) is an FDA-approved treatment for adults with treatment-resistant depression and certain severe depressive episodes. Offered in a calm, private clinical setting, SPRAVATO® provides a medically supervised option for individuals who continue to struggle despite traditional antidepressant therapy.

At Resolute, we combine advanced psychiatric care with a discreet, patient-centered experience — because hope should feel both accessible and dignified.

You Are Not Out of Options

If you've tried multiple antidepressants and still feel stuck, exhausted, or disconnected, SPRAVATO® may offer a new path forward.

Many patients pursue SPRAVATO® because they are:

• Tired of cycling through medications without meaningful relief
• Struggling with persistent depression despite therapy and medication
• Seeking a treatment that works differently than standard antidepressants

You are not failing treatment — the treatment may not have been right for you.

What Is SPRAVATO®?

SPRAVATO® is a prescription esketamine nasal spray, administered in-clinic under medical supervision and used alongside an oral antidepressant.

Unlike traditional antidepressants that target serotonin or norepinephrine, SPRAVATO® works through glutamate pathways, offering a distinct mechanism of action for depression that has not responded to standard care.

SPRAVATO® is not a take-home medication and is only available through certified healthcare providers.

What Does SPRAVATO® Treat?

SPRAVATO® is FDA-approved for adults with:

• Treatment-Resistant Depression (TRD)
  Depression that has not adequately improved after trying two or more antidepressants at appropriate doses and duration.
• Major Depressive Disorder with acute suicidal ideation or behavior
  Used in combination with an oral antidepressant as part of urgent psychiatric care.

Why Patients Choose SPRAVATO®

• FDA-approved for treatment-resistant depression
• Different mechanism than traditional antidepressants
• Administered in a controlled medical environment
• Structured treatment with close monitoring
• May provide symptom relief when other treatments have failed

Individual results vary, and our clinicians carefully assess whether this treatment aligns with your needs and medical history.

Am I a Candidate for SPRAVATO®?

You may qualify for SPRAVATO® if you:

• Are 18 years or older
• Have a diagnosis of Major Depressive Disorder
• Have tried two or more antidepressant medications without adequate improvement
• Continue to experience significant depressive symptoms
• Are able to attend in-clinic treatment sessions
• Are willing to take an oral antidepressant as part of treatment

SPRAVATO® may not be appropriate if you have:

• Uncontrolled high blood pressure
• Certain heart, blood vessel, or neurological conditions
• A history of aneurysm or vascular malformation
• Are pregnant or breastfeeding
• Certain active substance use concerns

If you're unsure whether you qualify, a consultation allows us to determine the safest and most appropriate next step.

What to Expect at Resolute

Step 1: Confidential Consultation

We review your symptoms, prior treatments, medical history, and insurance benefits to determine eligibility.

Step 2: In-Clinic Treatment

• Self-administration of SPRAVATO® under staff supervision
• Relaxation in a private treatment room
• Continuous monitoring of blood pressure and well-being
• Typical visit time: approximately two hours

Step 3: Ongoing Care

• A driver is required for discharge
• No driving until the next day
• Treatment frequency adjusted based on your response

Typical Treatment Schedule

Treatment is individualized, but many patients follow this structure:

• Weeks 1–4: Twice-weekly sessions
• Weeks 5–8: Weekly sessions
• Maintenance: Every 1–2 weeks, as clinically indicated

Your provider will tailor the plan based on effectiveness and tolerability.

Safety & Monitoring

SPRAVATO® is available only through a restricted safety program (REMS) due to the potential for sedation, dissociation, and temporary increases in blood pressure.

Common Temporary Side Effects May Include:

• Dizziness or lightheadedness
• Sedation or sleepiness
• Nausea
• Headache
• Dissociation or altered perception
• Temporary blood pressure elevation

All patients are monitored in-clinic to ensure safety prior to discharge.

Insurance & Payment

Many major insurance plans cover SPRAVATO® for qualifying patients, often with prior authorization.

Our team will assist with:

• Insurance verification
• Prior authorization support
• Clear explanation of expected costs

Coverage varies by plan.

Schedule Your SPRAVATO® Consultation

If depression has persisted despite your best efforts, SPRAVATO® may offer a new direction.

Interested in Spravato? Fill out this quick survey and one of our staff will reach out to let you know if you might qualify.

Resolute
319 Industrial Dr.
Longview, TX 75602
903-213-9120

Important Safety Information

SPRAVATO® may cause sedation, dissociation, and increases in blood pressure. Because of these risks, it must be administered in a certified healthcare setting with monitoring. Patients must not drive or operate machinery until the day after treatment following a full night's sleep. This content is for informational purposes only and does not replace professional medical advice. Treatment decisions are made by a licensed clinician.

Frequently Asked Questions

What Are Some Clinical Studies Showing The Efficacy Of SPRAVATO® (Esketamine)?

Esketamine was evaluated in multiple randomized, double-blind, placebo-controlled trials involving adults with treatment-resistant depression. In the TRANSFORM studies, patients receiving esketamine combined with an oral antidepressant demonstrated statistically significant reductions in depressive symptom scores compared to antidepressant plus placebo. The SUSTAIN-1 relapse prevention trial also showed that patients who continued esketamine after achieving response had a significantly lower risk of relapse compared to those switched to placebo. These studies supported FDA approval and ongoing REMS monitoring requirements.

Is SPRAVATO® The Only Available Form Of Esketamine?

SPRAVATO® is currently the only FDA-approved intranasal esketamine product for treatment-resistant depression in the United States. Some clinics may reference compounded ketamine products, which are chemically related but not identical and are not FDA-approved for depression. SPRAVATO® undergoes standardized manufacturing, REMS oversight, and defined dosing protocols. This level of regulatory review and safety monitoring is not present with compounded alternatives.

How Is Esketamine Different From IV Ketamine?

Esketamine is the S-enantiomer of ketamine and is delivered as a nasal spray in a controlled medical setting. Intravenous ketamine infusions are used off-label for depression but follow different dosing strategies and monitoring frameworks. SPRAVATO® operates under a REMS program, requires documented eligibility criteria, and includes structured follow-up protocols.

What Happens If I Miss A Treatment Session?

If a session is missed, we reassess symptom severity and determine whether the dosing schedule needs adjustment. Some patients resume their prior frequency. Others may require temporary modification depending on clinical response and duration since the last dose.

How Quickly Do Patients Typically Notice Improvement?

Response time varies. Some individuals report mood changes within the first several sessions. Others experience more gradual improvement across several weeks. Symptom tracking during follow-up visits helps determine whether the current schedule remains appropriate.

Can SPRAVATO® Be Used With Other Psychiatric Medications?

Yes, but medication interactions are reviewed carefully. Esketamine is prescribed alongside an oral antidepressant. We evaluate mood stabilizers, antipsychotics, stimulants, and blood pressure medications to ensure compatibility before initiating treatment.

Do You Serve Patients Outside Of Longview, Texas?

Yes. Resolute serves patients throughout East Texas within state lines. Individuals frequently travel from Tyler, Marshall, and Texarkana for in-clinic SPRAVATO® treatment. Follow-up planning may include coordination with local providers when appropriate.

What Medical Conditions May Affect Eligibility?

Uncontrolled hypertension, certain vascular abnormalities, or a history of aneurysm require careful evaluation. Because esketamine can temporarily elevate blood pressure, cardiovascular stability is assessed prior to treatment initiation. Substance use history is also reviewed to determine safety.

Is SPRAVATO® A Long-Term Treatment?

Some patients transition to maintenance dosing after initial response. Others discontinue after sustained improvement. Duration depends on symptom recurrence risk, response pattern, and tolerability. Treatment plans are individualized and reviewed regularly.